| Literature DB >> 28484209 |
Karthika Prasad1,2, G S Lekshmi3, Kola Ostrikov4, Vanessa Lussini1, James Blinco1, Mandhakini Mohandas3, Krasimir Vasilev4, Steven Bottle1, Kateryna Bazaka5,6,7, Kostya Ostrikov8,9,10.
Abstract
Reduced graphene oxide (rGO) is a promising antibacterial material, the efficacy of which can be further enhanced by the addition of silver nanoparticles (nAg). In this study, the mechanisms of antibacterial activity of rGO-nAg nanocomposite against several important human pathogenic multi-drug resistant bacteria, namely Gram-positive coccal Staphylococcus aureus and Gram-negative rod-shaped Escherichia coli and Proteus mirabilis are investigated. At the same concentration (100 µg/ml), rGO-nAg nanocomposite was significantly more effective against all three pathogens than either rGO or nAg. The nanocomposite was equally active against P. mirabilis and S. aureus as systemic antibiotic nitrofurantoin, and significantly more effective against E. coli. Importantly, the inhibition was much faster in the case of rGO-nAg nanocomposite compared to nitrofurantoin, attributed to the synergistic effects of rGO-nAg mediated contact killing and oxidative stress. This study may provide new insights for the better understanding of antibacterial actions of rGO-nAg nanocomposite and for the better designing of graphene-based antibiotics or other biomedical applications.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28484209 PMCID: PMC5431540 DOI: 10.1038/s41598-017-01669-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1SEM images of synthesized nanomaterials. (a) rGO nanosheets with a large number of reactive edges, (b) nAg nanoparticles of uniform size and near spherical shape, (c) rGO–nAg composite showing uniform distribution of nAg.
Figure 2Representative HRTEM images of (a) rGO–nAg nanocomposite, (b) lattice resolved image of nAg in rGO–nAg nanocomposite. (c) Size distribution histogram of nAg in rGO–nAg nanocomposite presented in (a).
Figure 3Reduction of GO to rGO and subsequent incorporation of nAg was confirmed spectroscopically: (a) FTIR spectra for GO and rGO; (b) XRD of rGO and rGO–nAg composite; (c) UV spectrum of nAg; (d) UV–Vis spectra for rGO and rGO–nAg composite.
Figure 4ESR spectrum of rGO–nAg recorded at room temperature.
Figure 5Well diffusion study. Representative plates of (a) P. mirabilis, (b) S. aureus, and (c) E. coli. Red circles indicate the zone of inhibition from wells loaded with nitrofurantoin; yellow circles indicate the zone of inhibition from wells loaded with rGO–nAg.
Figure 6Viable count of bacteria after exposure to (a) rGO, (b) nAg, (c) rGO–nAg composite, and (d) standard antibiotic nitrofurantoin.
The average zones of inhibition (in mm) of rGO, nAg, rGO–nAg, and nitrofurantoin.
| Isolates |
|
|
|
|---|---|---|---|
|
| |||
| 50 µg/ml | No zone | No zone | No zone |
| 100 µg/ml | No zone | No zone | No zone |
| 200 µg/ml | 18 ± 2 | 9 ± 1 | No zone |
|
| |||
| 100 µg/ml | No zone | No zone | 8 ± 1 |
|
| |||
| 100 µg/ml | 23 ± 2 | 25 ± 2 | 24 ± 1 |
|
| |||
| 100 µg/ml | 24 ± 2 | No zone | 26 ± 1 |
As expected, the zone of inhibition for rGO and nAg was concentration-dependent. The concentrations of 50 µg/ml and 100 µg/ml of rGO and nAg, respectively, were insufficient to inhibit the organisms tested. At these concentrations, nitrofurantoin inhibited P. mirabilis and S. aureus, but not E. coli. rGO–nAg nanomaterial composite showed strong activity, inhibiting all pathogens tested, including E. coli shown to be resistant to standard antibiotic.
Figure 7A symbolic representation of the mechanism of process of destruction of bacteria from the cumulative effect of cell-wrapping as well as cell - trapping mechanisms of rGO nanosheets and cell penetration of Ag nanomaterial.
Figure 8A symbolic representation of the mechanism by which the rGO–nAg nanoparticles kill the bacteria. The rGO punctures cell wall and enter the cytoplasm. Silver nanoparticles directly enter into the cell, induces oxidative stress and damage the cell contents.